Investment Strategy Aims to Accelerate Transition of Gene Therapy from Pre-clinical to Clinical Stage With Lucia Faccio Sofinnova Partners

Published: June 22, 2020, 4:20 p.m.

Lucia Faccio, Partner for the Sofinnova Telethon Fund at Sofinnova Partners talks about the recent creation of the Sofinnova Telethon Fund in Italy dedicated to early-stage investments in biotechnology companies that are addressing unmet medical needs of those suffering from rare and genetic diseases.  Lucia is particularly enthusiastic about a recent investment in Genespire, company with a game changing technology providing a platform that is a lentiviral gene therapy for treatment of metabolic diseases and another gene editing platform with a focus on treating primary immunodeficiencies.

#SofinnovaPartners #Biotech #geneticdiseases #Funding

SofinnovaPartners.com

Download the transcript here

Sofinnovagenespire